Zealand Pharma to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
Zealand Pharma (Nasdaq: ZEAL) will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021. Members of the senior management team are scheduled to present virtually at 9:40 a.m. ET / 3:40 p.m. CET. A live webcast will be available on the Company's website under 'Events & Presentations,' with an archived replay following the event. Zealand focuses on peptide-based medicines and has a strong pipeline, including the recently approved Zegalogue for severe hypoglycemia in diabetes patients.
- None.
- None.
Company announcement – No. 36/ 2021
Zealand Pharma to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
Copenhagen, DK and Boston, MA, U.S. June 3, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that members of its senior management team are scheduled to participate virtually in the Goldman Sachs 42nd Annual Global Healthcare Conference:
Goldman Sachs 42nd Annual Global Healthcare Conference
Date: Thursday, June 10, 2021
Presentation: 9:40 a.m. ET / 3:40 p.m. CET
A live webcast of the event will be available on the "Events & Presentations" page in the Investor section of the Company's website at https://www.zealandpharma.com/events-presentations. A replay of the webcast will be archived on the Company's website following the presentation.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development. Zealand markets V-Go®, abasal-bolus insulin delivery option for people with diabetes and has received approval for Zegalogue® (dasiglucagon), the first and only glucagon analogue for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 and above. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics. Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit www.zealandpharma.com.
For further information, please contact:
| Zealand Pharma Investor Relations |
| Claudia Styslinger |
| Argot Partners |
| investors@zealandpharma.com |
| Zealand Pharma Media Relations |
| David Rosen |
| Argot Partners |
| media@zealandpharma.com |
FAQ
What date will Zealand Pharma present at the Goldman Sachs Healthcare Conference?
What is the time of Zealand Pharma's presentation at the conference?
Where can I watch the Zealand Pharma presentation live?
What is Zealand Pharma known for?
What notable product has Zealand Pharma recently launched?
